SALIX PHARMACEUTICALS LTD Business Finance Contracts & Agreements
31 Contracts & Agreements
- Assignment Agreements (1 contract)
- Credit Agreements (2)
- Escrow Agreements (1)
- Exchange Agreements (1)
- Indenture Agreements (6)
- Loan Agreements (1)
- Note Agreements (6)
- Pledge Agreements (1)
- Purchase Agreements (2)
- Release Agreements (1)
- Repurchase Agreements (1)
- Stock Agreements (7)
- Underwriting Agreements (1)
- FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on April 1, 2015)
- FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on April 1, 2015)
- *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT... (Filed With SEC on February 28, 2014)
- $750,000,000 SalixPharmaceuticals, Ltd. 6.00% Senior Notes due 2021 Joinder to Registration Rights Agreement (Filed With SEC on January 2, 2014)
- SUPPLEMENTAL INDENTURE (Filed With SEC on January 2, 2014)
- $750,000,000 SALIX PHARMACEUTICALS, LTD. 6.00% Senior Notes due 2021 REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 27, 2013)
- ESCROW ANDSECURITY AGREEMENT (Filed With SEC on December 27, 2013)
- SALIXPHARMACEUTICALS, LTD. 6.00% SENIOR NOTES DUE 2021 INDENTURE DATED AS OFDECEMBER 27, 2013 U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE CROSS-REFERENCE TABLE* (Filed With SEC on December 27, 2013)
- SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN, AS AMENDED Approved by the Board: May 14, 2012 Approved by the Stockholders: June 14, 2012 (Filed With SEC on May 16, 2012)
- NOTE REPURCHASE AGREEMENT (Filed With SEC on March 16, 2012)
- SALIX PHARMACEUTICALS, LTD. as Issuer AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of March 16, 2012 1.5% Convertible Senior Notes due 2019 (Filed With SEC on March 16, 2012)
- FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on March 16, 2012)
- SALIX PHARMACEUTICALS, LTD. (A Delaware corporation) $600,000,000 1.50% Convertible Senior Notes Due 2019 PURCHASE AGREEMENT (Filed With SEC on March 16, 2012)
- 5,500,000 Shares Salix Pharmaceuticals, Ltd. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 19, 2009)
- SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN, AS AMENDED (Filed With SEC on June 11, 2009)
- Salix Pharmaceuticals, Inc., Mesalamine Controlled Release Capsules (Filed With SEC on May 6, 2009)
- WAIVER AND FIRST AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on August 5, 2008)
- Portions of this exhibit marked [*] are requested to be treated confidentially. MASTER PURCHASE AND SALE AND LICENSE AGREEMENT Between (Filed With SEC on May 10, 2007)
- CREDIT AGREEMENT Dated as of February 22, 2007 among SALIX PHARMACEUTICALS, LTD., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and (Filed With SEC on February 28, 2007)
- SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN (as amended June 15, 2006) (Filed With SEC on June 16, 2006)
- SALIX PHARMACEUTICALS, LTD. 2005 STOCK PLAN (Filed With SEC on March 16, 2006)
- ASSIGNMENT OF TRADEMARKS (Filed With SEC on August 9, 2004)
- SALIX PHARMACEUTICALS, LTD. 1996 STOCK OPTION PLAN (as amended through July 1, 2004) (Filed With SEC on August 9, 2004)
- Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. ASSET PURCHASE AGREEMENT (Filed With SEC on August 9, 2004)
- THIRD MODIFICATION TO COMMERCIAL PROMISSORY NOTE AND LOAN AND SECURITY AGREEMENT (Filed With SEC on May 10, 2004)
- SECOND MODIFICATION TO COMMERCIAL PROMISSORY NOTE (Filed With SEC on March 12, 2004)
- FIRST MODIFICATION TO COMMERCIAL PROMISSORY NOTE (Filed With SEC on November 14, 2003)
- SALIX PHARMACEUTICALS, LTD. COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on November 10, 2003)
- OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK (Filed With SEC on January 10, 2003)
- NEGATIVE PLEDGE AGREEMENT (Filed With SEC on November 14, 2002)
- COMMERCIAL PROMISSORY NOTE (Secured, Variable Rate) $7,000,000.00 Raleigh, North Carolina MASTER NOTE September 30, 2002 (Filed With SEC on November 14, 2002)
